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INTRODUCTION
Hepatocyte growth factor (HGF) is a heterodimeric molecule composed of a 69 kD α-chain and a 34 kD β-chain, known to be the ligand of the c-met membrane receptor tyrosine kinase, and initially characterized as a potent stimulator of DNA synthesis in hepatocytes (Nakamura et al., 1989; Rubin et al., 1993) . It is therefore thought to contribute in a major way to liver regeneration and, consistent with such a role, its plasma levels are increased in patients suffering from fulminant hepatic failure or liver cirrhosis (Tsubouchi et al., 1991) . In addition to this mitogenic role, HGF has been shown to regulate expression of various genes, such as the cytochrome P-450 (CYP) 7A1 gene, encoding the cholesterol 7α-hydroxylase involved in bile acid synthesis (Song et al., 2007) . CYPs involved in drug detoxification have also been demonstrated to be regulated by HGF (Kakizaki et al., 2007) . HGF treatment thus resulted in decreased expression of CYP1A2 and CYP3A4 at both mRNA and protein levels in primary human hepatocytes (Donato et al., 1998) ; CYP1A/2, CYP3A4 and also CYP2B6 activities were concomitantly decreased, suggesting a reduced metabolism of drugs administered during the course of human liver diseases associated with up-regulation of HGF production (e.g., viral or toxic fulminant hepatitis). Down-regulation of detoxication capacity has been similarly observed in rats during liver regeneration after partial hepatectomy (Habib DMD 28035 supplemented with 5 x 10 -5 M hydrocortisone hemisuccinate (Upjohn, Paris La Défense, France) and 2 % dimethyl sulfoxide, as already reported (Chouteau et al., 2001; Le Vee et al., 2008) . All experimental procedures complied with French laws and regulations and were approved by the National Ethics Committee.
RNA isolation and analysis.
Total RNA was isolated from cells using the TRIzol R reagent (Invitrogen). RNA was then subjected to reverse transcription-real time quantitative polymerase chain reaction (RT-qPCR) using the fluorescent dye SYBR Green methodology and an ABI Prism 7300 detector (Applied Biosystem, Foster City, CA), as already reported (Jigorel et al., 2005) . Gene primers for drug transporters, CYP2B6 and 18S RNA were exactly as previously described (Jigorel et al., 2006; Le Vee et al., 2008) . Other primers were CYP7A1 sense, AGACACACCTCGTGGTCCTC, CYP7A1 antisense, TTTCATTGCTTCTGGGTTCC, hypoxia-inducible factor (HIF)-1α sense, CCTGCTTGGTGCTGATTTG, HIF-1α antisense, GGCTGTGTCGACTGAGGAA, constitutive androstane receptor (CAR) sense, TGATCAGCTGCAAGAGGAGA, and CAR antisense, AGGCCTAGCAACTTCGCATA.
Relative quantification of the steady-state target mRNA levels was calculated after normalization to 18S RNA level, used here as an internal control.
Western-blot analysis.
Crude membrane extracts were prepared from primary human hepatocytes as previously described (Jigorel et al., 2006) . Proteins were then separated on polyacrylamide gels and electrophoretically transferred to nitrocellulose membranes. After blocking in Tris-buffered saline containing 4 % bovine serum albumin, membranes were incubated overnight at 4°C
with primary antibodies directed against NTCP (SLC10A1) (Kullak-Ublick et al., 1997) , This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
Effects of HGF treatment on expression of referent HGF target genes.
Primary human hepatocytes from 6 liver donors were exposed to HGF for 8 h, 24 h or 48 h. HGF was first used at a concentration (20 ng/ml) close to those used for treating primary human hepatocytes (Donato et al., 1998; Song et al., 2007; Barreiros et al., 2009) ; this HGF concentration did not exert toxicity as demonstrated by phase-contrast microscopic examination of the cultures and analysis of cell viability using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide colorimetric assay (data not shown). As shown in Fig. 1 , HGF was shown to markedly repress CYP7A1 mRNA expression and to concomitantly induce HIF-1α mRNA levels, at all three time intervals. Because CYP7A1 and HIF-1α can be considered as prototypical markers known to be down-regulated or up-regulated by HGF, respectively (Tacchini et al., 2004; Song et al., 2007) , primary human hepatocytes were responsive to HGF and thus suitable for investigating HGF effects towards drug transporter expression.
Effects of HGF treatment on drug transporter mRNA expression.
The effects of HGF treatment on SLC transporter mRNA expression were first analyzed by RT-qPCR. As shown in Fig. 2A among the transporters affected by HGF, followed by OATP1B1 (repression by a 3.8-foldfactor), NTCP (repression by a 3.7-fold factor), OAT2 (repression by a 2.9-fold factor) and OATP2B1 (repression by a 2.8-fold factor).
The effects of HGF treatment on ABC transporter mRNA expression were next studied. As shown in Fig. 2B , expression of BCRP, MRP2, MRP3 and MRP4 (ABCC4) remained unchanged in hepatocytes exposed to HGF for 8 h, 24 h or 48 h, when compared to untreated counterparts. By contrast, HGF down-regulated BSEP (ABCB11), whatever the time of exposure; BSEP mRNA levels in hepatocytes exposed to HGF for 48 h were thus reduced by a 4.5-fold factor when compared to untreated cells. HGF treatment was also found to induce MDR1 mRNA levels by a 2-fold factor after a 8 h-exposure to HGF (Fig. 2B) ; this up-regulation of MDR1 expression was however transient since longer exposure to HGF (24 h and 48 h) failed to alter MDR1 mRNA levels.
The dose-response relationship for HGF effects toward transporter expression was then characterized. For this purpose, we have only analyzed transporters whose mRNA expression was decreased by at least 50% in human hepatocytes exposed to 20 ng/ml HGF for 48 h, i.e. NTCP, OATP2B1, OATP1B1, OCT1, OAT2 and BSEP (Fig. 2) . These transporters were similarly down-regulated by 50 ng/ml HGF (Fig. 3) . HGF used at 5 ng/ml also significantly repressed transporter expression, although in a more moderate manner for NTCP, OATP2B1, OATP1B1 and OAT2 (Fig. 3) . Lower concentrations of HGF such as 0.005, 0.05 or 0.5 ng/ml, failed to obviously alter expression of transporters; they also did not affect CYP7A1 mRNA levels, which were, by contrast, markedly reduced by higher concentrations of HGF (Fig. 3) .
Effects of HGF treatment on drug transporter protein expression.
To determine whether some of the changes in transporter mRNA levels induced by HGF treatment also occur at the protein level, western-blot analysis of crude membranes from HGF-treated primary human hepatocytes and untreated counterparts was performed. As indicated in Fig. 4 , HGF treatment for 48 h reduced NTCP, OATP2B1 and OATP1B1 levels.
By contrast, HGF induced P-glycoprotein and BCRP expression, but failed to obviously alter MRP2 and MRP3 expression (Fig. 4) .
Effects of HGF treatment on transporter activities.
Owing to the limited availability of human hepatocytes, we focused on the effects of HGF treatment on activities of NTCP, OATPs and OCT1, whose mRNA expressions were among the most repressed by HGF ( Fig. 2A ). As shown in 
Correlation analysis of the repressing effects of HGF, tumor necrosis factor (TNF)-α and interleukin (IL)-6 on drug transporter mRNA expression in human hepatocytes.
TNF-α and IL-6 are pro-inflammatory cytokines whose plasma levels are increased and correlated with up-regulated HGF levels during fulminant hepatic failure (Sekiyama et al., 1994) and which have been previously demonstrated to repress various hepatic drug transporters (Le Vee et al., 2009) . In order to search for a putative correlation between these alterations of drug transporter expression occurring in primary human hepatocytes exposed to were ranked from the most repressed transporter to the less repressed, according to mRNA expression levels. Correlations were analyzed using the Spearman's rank correlation method.
Results indicated that the effects of HGF were significantly correlated with those of TNF-α ( Fig. 6 ). By contrast, HGF effects on drug transporter expression were not correlated with those of ).
Effect of HGF treatment on phenobarbital-mediated regulation of drug transporters.
Because HGF has been previously shown to alter regulation of some CYPs in response to chemical inducers (Donato et al., 1998) , whether HGF may also act on xenobiotic-mediated regulation of transporters was finally investigated. For this purpose, we focused on phenobarbital-related induction of ABC transporters because (i) phenobarbital is one of the chemical inducers whose effects towards CYPs, especially cyp2b10, is impaired by HGF (Koike et al., 2007) , (ii) the xenobiotic receptor CAR, which is thought to mediate many of the effects of phenobarbital, has been shown to be down-regulated by HGF in mouse hepatocytes and human hepatoma cells (Kakizaki et al., 2007; Osabe et al., 2008) and (iii) phenobarbital appears to be one of the most robust inducers of drug transporters such as MDR1, MRP2 and BCRP in primary human hepatocytes (Jigorel et al., 2006) . HGF was first demonstrated to repress mRNA expression of CAR in primary human hepatocytes by a 3.8-fold factor (Fig. 7A ), which agrees with previous data from human hepatoma HepG2 cells (Osabe et al., 2008) . HGF was next shown to markedly inhibit induction of the CAR This article has not been copyedited and formatted. The final version may differ from this version. moreover, some of these transporters, i.e. NTCP, OATP2B1 and OATP1B1, are also downregulated at protein levels and NTCP, OATP and OCT1 transport activity are concomitantly reduced. Taken together, these data indicate that these sinusoidal uptake transporters likely constitute major targets of HGF in human hepatocytes; they may also similarly represent putative targets of HGF in rodent hepatocytes because some of them have been reported to be down-modulated in regenerating rat liver, a physio-pathological situation associated with upregulation of HGF (Gerloff et al., 1999) , or in liver of HGF-overexpressing mice (Kakizaki et al., 2007) . It should however be kept in mind that OATP1B3 mRNA levels were not altered in HGF-treated human hepatocytes; similarly, HGF did not change Oatp1 mRNA expression in primary rat hepatocytes (Iwakiri et al., 2008) . Taken together, these data thus demonstrate that HGF impairs expression of a majority, but not the totality, of uptake SLC transporters in hepatocytes.
Besides uptake transporters, HGF also acts on expression of efflux ABC transporters in human hepatocytes, but in a rather different and more limited manner ( and protein levels. MRP2 levels have also been shown not to be altered during rat liver regeneration after partial hepatectomy, whereas mdr1b/P-glycoprotein expression was induced (Gerloff et al., 1999; Vos et al., 1999) , thus fully supporting the conclusion that these hepatic ABC transporters are differentially sensitive to growth factors. MRP3, located at the basolateral pole of hepatocytes and thought to be involved in back transport of drugs from hepatocytes to blood (Borst et al., 2006) , was also not targeted by HGF. Physiological and pathological relevance of HGF effects toward human hepatic transporter expression remains to be precisely described. HGF exposure is however likely to decrease sinusoidal uptake of drugs, owing to its global repressing effect toward uptake transporters. By contrast, biliary efflux of drugs may be preserved (for drugs handled by
MRP2) or even enhanced (for drugs handled by P-glycoprotein or BCRP). Taken together, these data indicate that HGF may reduce xenobiotic accumulation in hepatocytes, through
This article has not been copyedited and formatted. The final version may differ from this version. Indeed, HGF plasma levels in these patients can reach values (5-10 ng/ml) (Tsubouchi et al., 1991) , that are in the range of HGF concentrations affecting drug transporter expression (Fig.   3 ). This suggests that hepatocytes from such patients exhibit HGF-mediated repression of uptake transporters associated with concomitant down-regulation of CYP expression, which is likely to result in an overall decrease of drug detoxification capacity of the liver. Such a down-regulation of the hepatic drug elimination pathway may moreover be reinforced by the up-regulations of pro-inflammatory cytokines such as TNF-α, IL-1β and IL-6, which occur during fulminant hepatitis (Muto et al., 1988; Sekiyama et al., 1994) , and which are presumed to also contribute to repression of both drug uptake transporters and CYPs in human hepatocytes (Abdel-Razzak et al., 1993; Le Vee et al., 2008; Le Vee et al., 2009 ).
This article has not been copyedited and formatted. The final version may differ from this version. In conclusion, the current data demonstrate that HGF rather differentially regulates transporter expression in human hepatocytes, i.e. it markedly repress most of the uptake SLC transporters whereas expression of most of the efflux transporters is unchanged or increased.
Such changes may likely contribute to alterations of pharmacokinetics in patients suffering from diseases associated with increased plasma levels of HGF.
This article has not been copyedited and formatted. The final version may differ from this version. Primary human hepatocytes were either untreated (UNT) or exposed to 20 ng/ml HGF for 48 h. NTCP, OATP and OCT1 activities were then determined using radiolabeled substrates as described under Materials and Methods. Data are expressed relatively to transporter activity found in untreated cells, arbitrarily set at the value of 100 %; they are the means + SEM of values from four independent hepatocytes populations. *, p<0.05 when compared to untreated cells. 
